TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25640408

Group type: EXPERIMENTAL
Intervention: Atropine 1% in 1 eye
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Atropine-treated eyes
Number of subjects: 200

Group type: COMPARATOR
Intervention: Untreated fellow eye
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Progressors
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Baseline myopia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Myopic change in untreated eyes
Number of subjects: 200
Study: 24096465

Group type: EXPERIMENTAL
Intervention: Moderate-intensity, home-based walking program
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study: 21846395

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 73
Study: 19948613

Group type: EXPERIMENTAL
Intervention: Oral 25% dextrose treatment, given 2 minutes before the injection
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact, initiated 2 minutes before the injection and persisting throughout the procedure
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Combination of oral 25% dextrose treatment and skin-to-skin contact
Number of subjects: 640

Group type: COMPARATOR
Intervention: No analgesia (routine)
Number of subjects: 640
Study: 16493214

Group type: EXPERIMENTAL
Intervention: End-firing Nd:YAG laser
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Side-firing Nd:YAG laser
Number of subjects: 62
Study: 15035552

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Utrogestan, Besins International) 400 mg starting on the day of oocyte retrieval (Group A)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Vaginal progesterone (Utrogestan, Besins International) 400 mg starting on the day of embryo transfer (Group B)
Number of subjects: 103
Study: 10834419

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 40 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9569795

Group type: EXPERIMENTAL
Intervention: Piroxicam FDDF 40 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aspirin 500 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8371917

Group type: EXPERIMENTAL
Intervention: PhXA41 (35 micrograms/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PhXA41 (60 micrograms/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PhXA41 (115 micrograms/ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PhXA41 (all concentrations)
Number of subjects: 60
Study: 3524514

Group type: EXPERIMENTAL
Intervention: RS-86 (muscarinic agonist) administered orally at maximum individually tolerated dose levels for eight days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study: 31753521

Group type: EXPERIMENTAL
Intervention: MHADRO intervention group
Number of subjects: 836
Study: 29505772

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg every 6 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acetaminophen 650 mg every 6 hours
Number of subjects: 100
Study: 26618259

Group type: EXPERIMENTAL
Intervention: Digital impression technique
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional impression technique
Number of subjects: 42
Study: 24420746

Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: efavirenz 600 mg with rifampin 600 mg/day
Number of subjects: 12
Study: 22372850

Group type: EXPERIMENTAL
Intervention: Expert source condition (psychological oncological expert talking about cancer patients' experiences)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Former patient source condition
Number of subjects: 154
Study: 20934562

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 4124

Group type: COMPARATOR
Intervention: No hormone replacement therapy (non-HRT)
Number of subjects: 4124

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 4124
Study: 18547757

Group type: EXPERIMENTAL
Intervention: Duloxetine (20mg BID for 2 weeks, then 40mg BID for 10 weeks)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 265
Study: 15199033

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment (fluence of 3 J/cm2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (untreated skin)
Number of subjects: 40
Study: 11325157

Group type: EXPERIMENTAL
Intervention: Hi-Dense fillings (condensable metal-reinforced glass ionomer cement)
Number of subjects: 17
Study: 9012902

Group type: EXPERIMENTAL
Intervention: Helium/oxygen (He/O2) inhalation for 90 minutes
Number of subjects: 12
Study: 7936810

Group type: EXPERIMENTAL
Intervention: IUGR infants
Number of subjects: 47
Study: 3060885

Group type: EXPERIMENTAL
Intervention: CGP 12.103 A
Number of subjects: 41

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 41
Study: 30316339

Group type: EXPERIMENTAL
Intervention: Living liver donation (LLD) related
Number of subjects: 2683

Group type: EXPERIMENTAL
Intervention: Living liver donation (LLD) unrelated
Number of subjects: 2683

Group type: EXPERIMENTAL
Intervention: Various factors influencing attitude towards LLD
Number of subjects: 2683
Study: 28663621

Group type: EXPERIMENTAL
Intervention: Oral clonidine (0.3 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 26557673

Group type: EXPERIMENTAL
Intervention: Oral supplementation with antioxidants/omega 3 fatty acids (A/ω3) for three months
Number of subjects: 148

Group type: COMPARATOR
Intervention: Computer users (CUG)
Number of subjects: 148
Study: 23301559

Group type: EXPERIMENTAL
Intervention: Benzocaine mucoadhesive patches (20%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 30
Study: 21970447

Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Active control (AC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Endurance + resistance training (ER)
Number of subjects: 38
Study: 18450232

Group type: EXPERIMENTAL
Intervention: 4 mg of ondansetron intravenously 30 minutes prior to completion of the surgery
Number of subjects: 372

Group type: COMPARATOR
Intervention: 4 mg of ondansetron intravenously prior to the induction of anesthesia
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 372
Study: 17557432

Group type: EXPERIMENTAL
Intervention: 60 mg of pseudoephedrine sulfate and 10 mg of domperidone at bedtime for 30 days (open-label trial)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 60 mg of pseudoephedrine sulfate plus 10 mg of domperidone (placebo-controlled trial)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 30 mg of pseudoephedrine sulfate plus 10 mg of domperidone (placebo-controlled trial)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Drug combination (pseudoephedrine sulfate and domperidone)
Number of subjects: 30
Study: 15058039

Group type: EXPERIMENTAL
Intervention: dexamethasone and pentoxifylline
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: dexamethasone
Number of subjects: 42

Group type: COMPARATOR
Intervention: antibiotics only
Number of subjects: 42
Study: 10716106

Group type: EXPERIMENTAL
Intervention: Closed treatment (77 patients)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Open treatment (65 patients)
Number of subjects: 137
Study: 9360163

Group type: EXPERIMENTAL
Intervention: Low temperature WBHT for 1 hour at 40 degrees C, repeated 96 hours later
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High temperature WBHT for 1 hour at 42 degrees C, repeated 96 hours later
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WBHT in patients on protease inhibitor/triple drug therapy
Number of subjects: 30
Study: 1550466

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/d
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/d and 20 mg/d
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study: 3898350

Group type: COMPARATOR
Intervention: Cimetidine maintenance therapy
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 86
Study: 30889827

Group type: EXPERIMENTAL
Intervention: Taekwondo training (TKD)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 29106772

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training for 6 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 46
Study: 27528611

Group type: EXPERIMENTAL
Intervention: 3 mL hyaluronic acid (HA) injection at the end of arthroscopic meniscectomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Meniscectomy alone
Number of subjects: 90
Study: 23924070

Group type: EXPERIMENTAL
Intervention: KOH 10% solution applied two times a day until lesions disappeared
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cryotherapy performed with liquid nitrogen spray, repeated weekly for 4 weeks
Number of subjects: 30
Study: 22699672

Group type: EXPERIMENTAL
Intervention: Prefabricated fiber post (LP)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Customized fiber post (ES)
Number of subjects: 345

Group type: COMPARATOR
Intervention: No post retention (A)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Teeth with one coronal wall
Number of subjects: 345

Group type: COMPARATOR
Intervention: Teeth with two coronal walls
Number of subjects: 345

Group type: COMPARATOR
Intervention: Teeth with three coronal walls
Number of subjects: 345

Group type: COMPARATOR
Intervention: Teeth without coronal walls
Number of subjects: 345
Study: 20196969

Group type: EXPERIMENTAL
Intervention: 0.9 g of n-3 polyunsaturated fatty acids (n-3 PUFA) daily for 24 weeks
Number of subjects: 138

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 138
Study: 17540474

Group type: EXPERIMENTAL
Intervention: Plate size 17 cm
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Plate size 22 cm
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Plate size 26 cm
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Smallest plate in third study
Number of subjects: 119
Study: 15242867

Group type: EXPERIMENTAL
Intervention: Algorithm guided by oesophageal Doppler flowmetry to maintain a stroke index above 35 ml/m2
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional haemodynamic management
Number of subjects: 174
Study: 11591936

Group type: EXPERIMENTAL
Intervention: Laparoscopic hepatectomy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Open hepatectomy
Number of subjects: 55
Study: 9676822

Group type: COMPARATOR
Intervention: m-CPP (0.08 mg/kg i.v.) + placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: m-CPP (0.08 mg/kg i.v.) + ondansetron (0.15 mg/kg i.v.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: ondansetron (0.15 mg/kg i.v.) + placebo
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 11
Study: 8053580

Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 40 mg/min
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 60 mg/min
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 75 mg/min
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 150 mg/min
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 300 mg/min
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 600 mg/min
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 1200 mg/min
Number of subjects: 56
Study: 2922026

Group type: EXPERIMENTAL
Intervention: Silver nitrate drops
Number of subjects: 12431

Group type: EXPERIMENTAL
Intervention: Erythromycin ophthalmic ointment
Number of subjects: 12431

Group type: EXPERIMENTAL
Intervention: Tetracycline ophthalmic ointment
Number of subjects: 12431

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 12431
Study: 29575232

Group type: EXPERIMENTAL
Intervention: Narcotrend Index-guided propofol delivery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard clinical parameters for propofol delivery (Control)
Number of subjects: 40
Study: 27997805

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) set at 40 L/min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard nonocclusive facial mask
Number of subjects: 15
Study: 25271991

Group type: EXPERIMENTAL
Intervention: Icare Pro rebound tonometer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tono-Pen XL tonometer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dependent eye in lateral decubitus position
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both spherical equivalents and axial lengths
Number of subjects: 50
Study: 22915617

Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (ADA+MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapies (control group)
Number of subjects: 0
Study: 21154013

Group type: EXPERIMENTAL
Intervention: 30MIN (75 g isomaltulose, 75% reduced insulin dose)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 60MIN
Number of subjects: 7

Group type: COMPARATOR
Intervention: 90MIN
Number of subjects: 7

Group type: COMPARATOR
Intervention: 120MIN
Number of subjects: 7
Study: 18279292

Group type: EXPERIMENTAL
Intervention: Occlusive dressings
Number of subjects: 76

Group type: COMPARATOR
Intervention: Gauze dressings
Number of subjects: 76
Study: 16553542

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 12716333

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/2% copolymer dentifrice
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group (unspecified)
Number of subjects: 504
Study: 16100152

Group type: EXPERIMENTAL
Intervention: Exercise training plus activity training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Exercise training plus lecture series
Number of subjects: 43

Group type: COMPARATOR
Intervention: Exercise training alone
Number of subjects: 43
Study: 10341322

Group type: EXPERIMENTAL
Intervention: Amoxycillin and lansoprazol (double-blind placebo-controlled crossover study)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study: 7499109

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate 22.5 mg/m2 every 6 hours
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate 30 mg/m2 every 6 hours
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (various doses)
Number of subjects: 19
Study: 1775522

Group type: EXPERIMENTAL
Intervention: Minaprine 200 mg per day
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Minaprine 300 mg per day
Number of subjects: 112

Group type: COMPARATOR
Intervention: Imipramine 150 mg per day
Number of subjects: 112
Study: 6924676

Group type: EXPERIMENTAL
Intervention: Community psychiatric nursing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Out-patient psychiatrist follow-up
Number of subjects: 0
Study: 31940222

Group type: EXPERIMENTAL
Intervention: ACLR (Anterior Cruciate Ligament Reconstruction)
Number of subjects: 618

Group type: COMPARATOR
Intervention: ACLR + LET (Lateral Extra-articular Tenodesis)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: ACLR
Number of subjects: 618

Group type: COMPARATOR
Intervention: ACLR + LET
Number of subjects: 618

Group type: COMPARATOR
Intervention: ACLR and ACLR + LET
Number of subjects: 618
Study: 27830357

Group type: EXPERIMENTAL
Intervention: Ulinastatin (10,000 U/kg before anesthesia and 5000 U/kg daily on postoperative days 1 to 3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 80
Study: 25837879

Group type: EXPERIMENTAL
Intervention: Self‐Adjusting File (SAF)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Conventional syringe irrigation (CSI)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: EndoActivator (EA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Negative control group (5 teeth)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Positive control group (5 teeth)
Number of subjects: 70
Study: 23793338

Group type: EXPERIMENTAL
Intervention: Ablative full-face resurfacing using short-pulsed and dual-mode Er:YAG laser
Number of subjects: 22
Study: 21104251

Group type: EXPERIMENTAL
Intervention: Compression stocking (CS) above the knee exerting 18 mmHg for 1 week (day and night)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC) on the foot for 1 week (at night)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Comparison of CS vs IPC
Number of subjects: 57
Study: 19694636

Group type: EXPERIMENTAL
Intervention: Celecoxib (100 mg, n = 74)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg, n = 69)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo (n = 67)
Number of subjects: 210
Study: 17445350

Group type: EXPERIMENTAL
Intervention: Arachidonate-enriched TAG supplementation (838 mg ARA/d for 2 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo group (dietary intakes of arachidonic acid 179 (se13) mg/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Arachidonate-enriched TAG supplementation
Number of subjects: 24
Study: 15451546

Group type: EXPERIMENTAL
Intervention: Deramciclane 30 mg tablet administered after a high-fat meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Deramciclane 30 mg tablet administered after an overnight fast
Number of subjects: 18
Study: 11437029

Group type: EXPERIMENTAL
Intervention: Atrial pacing at maximum rate of 120/minute
Number of subjects: 55
Study: 9728840

Group type: EXPERIMENTAL
Intervention: Sitting position during CSE induction
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lateral recumbent position during CSE induction
Number of subjects: 22
Study: 8070502

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3046297

Group type: EXPERIMENTAL
Intervention: Whole rice
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Blended rice
Number of subjects: 18

Group type: COMPARATOR
Intervention: Whole potato
Number of subjects: 18

Group type: COMPARATOR
Intervention: Blended potato
Number of subjects: 18
Study: 30072135

Group type: EXPERIMENTAL
Intervention: PACRR scale (19-item scale) administered to physicians
Number of subjects: 333
Study: 27556348

Group type: EXPERIMENTAL
Intervention: Intracoronary verapamil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 25641045

Group type: EXPERIMENTAL
Intervention: Olopatadine, a second-generation antihistamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 24228847

Group type: EXPERIMENTAL
Intervention: 200 mg/day vitamin C for 3 months (group 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200 mg/day vitamin C for 3 months (group 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (both groups)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No vitamin C supplementation (group 2)
Number of subjects: 100
Study: 21864352

Group type: EXPERIMENTAL
Intervention: Non-operative treatment with a sling
Number of subjects: 350

Group type: COMPARATOR
Intervention: Plate fixation
Number of subjects: 350
Study: 20713675

Group type: EXPERIMENTAL
Intervention: Artemether and lumefantrine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lumefantrine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Artemether and dihydroartemisinin
Number of subjects: 50
Study: 17444040

Group type: EXPERIMENTAL
Intervention: KS‐3Ai group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: AcrySof IQ group
Number of subjects: 88

Group type: COMPARATOR
Intervention: AcrySof Natural group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: AcrySof IQ and KS‐3Ai groups
Number of subjects: 88
Study: 16319603

Group type: EXPERIMENTAL
Intervention: Aggressive acid-suppressive therapy for 4 months
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 72
Study: 12146728

Group type: EXPERIMENTAL
Intervention: Filtration strategies II-IV (with leukocyte filtration)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group I (without leukocyte filtration)
Number of subjects: 80
Study: 10214759

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 59
Study: 8929247

Group type: EXPERIMENTAL
Intervention: Myrin tablets (300 mg rifampicin, 150 mg isoniazid, 600 mg ethambutol HCl)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference (300 mg rifampicin, 200 mg isoniazid, 600 mg ethambutol HCl)
Number of subjects: 20
Study: 1964020

Group type: EXPERIMENTAL
Intervention: Guar gum (31.7 g per day for 6 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soluble gums (average of 19.5 g of added fiber per day for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low fiber diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet with cellulose (insoluble fiber)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboxymethylcellulose gum, karaya gum, locust bean gum (soluble fibers)
Number of subjects: 0
Study: 88343

Group type: EXPERIMENTAL
Intervention: 50%‐letters condition (letters trials)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 50%‐letters condition (no letters trials)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control trials
Number of subjects: 50
Study: 31121250

Group type: EXPERIMENTAL
Intervention: Spanish version of the Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 242
Study: 29039153

Group type: EXPERIMENTAL
Intervention: Single-shot supraclavicular block (GSCB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single-shot interscalene block (GISB)
Number of subjects: 50
Study: 26547503

Group type: EXPERIMENTAL
Intervention: HbA1c screening
Number of subjects: 6030

Group type: EXPERIMENTAL
Intervention: Two-step screening approach
Number of subjects: 6030